Korea FDA Raids Chong Kun Dang On Kickback Allegations
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Reflecting the Korean government's bid to crack down on medical kickbacks, Korea FDA investigators, armed with a search and seizure warrant, raided the headquarters and four branches of Chong Kun Dang Pharmaceutical following allegations that the pharma is offering illegal rebates ahead of the launch of the anti-rebate law Nov. 28
You may also be interested in...
Korea Trade Commission Launches Kickback Probes Of Pharmaceutical Firms Following Similar Action By Drug Regulators
SEOUL - To underscore the government's crackdown on kickbacks ahead of the implementation of a new law on the topic slated to become effective in late November, South Korea's Fair Trade Commission is launching probes of several Korean pharmaceutical firms suspected of providing illicit payments to hospitals and doctors
Korea Trade Commission Launches Kickback Probes Of Pharmaceutical Firms Following Similar Action By Drug Regulators
SEOUL - To underscore the government's crackdown on kickbacks ahead of the implementation of a new law on the topic slated to become effective in late November, South Korea's Fair Trade Commission is launching probes of several Korean pharmaceutical firms suspected of providing illicit payments to hospitals and doctors
South Korea's Health Ministry Unveils Provisions For November's Anti-rebate Law
SEOUL - South Korea's Ministry of Health and Welfare outlined detailed provisions to implement a new "anti-rebate law," which will enable courts to punish both contributors and receivers of rebates. Passed overwhelmingly by South Korea's National Assembly on April 28, the law goes into effect Nov. 28, and will be enforced by the ministry.Under the new regulations, pharmas will be able to offer "sample" drugs as long as they are offered the "minimum packing unit," said the ministry, adding that they will also be able to offer minimal amounts of drugs and research fees to those conducting clinical trials